Precigen Inc (PGEN)
Healthcare
Biotechnology
6.50 $
-1.2%
vs. previous close
Closing price · As of: 4. Aug 2026
All figures as a percentage of total assets in the same period.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 50.9% | 48.8% | 45.5% | 36.7% | 32.4% | 41.3% | 70.5% | 65.7% | 61.6% | 75.7% | 73.6% | 73.3% | |
| 8.0% | 5.3% | 5.0% | 13.0% | 12.8% | 29.6% | 20.3% | 4.7% | 13.5% | 8.4% | 19.3% | 5.4% | |
| 42.6% | 38.7% | 41.6% | 33.2% | 26.7% | 34.3% | 67.4% | 62.3% | 58.6% | 70.7% | 62.5% | 40.6% | |
| 6.9% | 7.4% | 1.0% | 0.9% | 1.4% | 0.9% | 0.8% | 0.8% | 0.6% | 0.6% | 2.8% | 19.3% | |
| – | – | 0.0% | 0.0% | – | – | 0.0% | – | – | 1.8% | 6.1% | 10.6% | |
| 3.2% | – | – | – | – | – | – | – | – | – | – | – | |
| 17.8% | 19.3% | 17.6% | 19.7% | 34.1% | 29.9% | 13.2% | 14.9% | 14.9% | 8.9% | 9.7% | 11.0% | |
| 20.6% | 21.2% | 26.9% | 28.7% | 7.0% | 5.7% | 3.1% | 3.2% | 3.7% | 2.0% | 2.0% | 2.1% | |
| 19.9% | 22.6% | 21.5% | 28.1% | 41.0% | 33.7% | 73.5% | 110.9% | 136.1% | 75.6% | 86.6% | 85.4% | |
| 14.8% | 17.2% | 15.2% | 21.3% | 31.5% | 25.4% | 14.8% | 18.6% | 22.8% | 18.7% | 23.8% | 15.2% | |
| 0.7% | 0.6% | 0.8% | 1.0% | 1.7% | 1.2% | 0.7% | 0.7% | 0.9% | 0.7% | 0.7% | 0.8% | |
| 1.2% | 1.2% | 1.1% | 3.5% | 6.6% | 5.2% | 2.4% | 2.4% | 3.8% | 3.7% | 7.7% | 1.9% | |
| – | – | – | – | – | – | – | – | – | 54.2% | 59.5% | 67.5% | |
| 80.1% | 77.4% | 78.5% | 71.9% | 59.0% | 66.3% | 26.5% | -10.9% | -36.1% | 24.4% | 13.4% | 14.6% | |
| -921.1% | -1,012.9% | -1,300.6% | -1,474.4% | -2,798.0% | -2,481.0% | -1,439.2% | -1,665.4% | -2,131.1% | -1,353.4% | -1,494.9% | -1,694.7% | |
| 119.5% | 130.3% | 164.8% | 184.8% | 345.0% | 330.5% | 201.6% | 228.2% | 290.9% | 173.1% | 199.8% | 225.8% |
Data as of: August 4, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.